共 103 条
[1]
Aktas D(2002)CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm Gynecol Oncol 86 124-128
[2]
Guney I(2010)Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide Br J Cancer 102 1003-1009
[3]
Alikasifoglu M(2009)Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project Cancer Res 69 2956-2965
[4]
Bray J(2009)Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer J Clin Oncol 27 1753-1760
[5]
Sludden J(2011)The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies Mutagenesis 26 437-446
[6]
Griffin MJ(1993)Relationship between genotype and function of the human CYP1A1 gene J Toxicol Environ Health 40 309-316
[7]
Canova C(2005)Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312-9318
[8]
Hashibe M(2010)Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study Breast Cancer Res 12 R26-594
[9]
Simonato L(2010)Personalized treatment of early-stage breast cancer: present concepts and future directions Cancer Treat Rev 36 584-200
[10]
Chan S(2004)Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol Sci 25 193-526